Evidence map›Paper›PMID 33203264›Full record

ArticleThe Journal of international medical research2020

Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report.

Jingxian Chen, Chien-Shan Cheng, Jie Chen, Lingling Lv, Xiaoheng Shen, Lan Zheng

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jingxian ChenDepartment of Traditional Chinese Medicine, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, China.
Chien-Shan ChengDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jie ChenDepartment of Orthopedics, Shanghai Institute of Traumatology and Orthopedics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Lingling LvDepartment of Traditional Chinese Medicine, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, China.
Xiaoheng ShenDepartment of Traditional Chinese Medicine, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, China.
Lan ZhengDepartment of Traditional Chinese Medicine, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-4393-9264
Ruijin Hospital · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to report a rare case of head and neck adenocarcinoma with an unknown primary site in a 59-year-old man. After disease progression followed by multiple cycles of chemotherapy and radiotherapy, genetic screening using next-generation sequencing identified vascular endothelial growth factor A amplification and the TP53 R209Kfs mutation. Treatment with the multi-targeted protein kinase inhibitor sorafenib controlled the patient's symptoms and improved his quality of life.

Indexed as

AdenocarcinomaNeoplasms, Unknown PrimaryHumansMaleMiddle AgedQuality of LifeSorafenibVascular Endothelial Growth Factor ASorafenibVascular Endothelial Growth Factor Aadenocarcinomaadverse eventsCancer of unknown primaryhead and neck cancernext-generation sequencingsorafenib

Identifiers

PMID33203264
PMCPMC7683926
OpenAlexW3103280654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.